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A B S T R A C T   
DiGeorge Syndrome (DGS) Critical Region 8 (DGCR8) is a primary candidate gene in they DGS. The DGCR8 microprocessor complex subunit is an essential cofactor 
in the canonical miRNA biogenesis which is involved in diverse cellular functions such as cell fate decisions, apoptosis and different signaling pathways. However, the 
role of DGCR8 in these processes or development of DGS is not fully understood. Here we present a heterozygous DGCR8 mutant human embryonic stem cell line 
(HuES9DGCR8+/− ) created by the CRISPR/Cas9 system. The generated HuES9DGCR8+/− cells maintain normal karyotype, morphology, pluripotency and differentiation 
capacity into all three germ layers.   
Resource Table  
Unique stem cell line 
identifier 
HVRDe009-A-1 
Alternative name(s) of 
stem cell line 
HuES9DGCR8+/- 
Institution Research Centre for Natural Sciences, Eötvös Loránd 
Research Network 
Contact information of 
distributor 
Ágota Apáti, apati.agota@ttk.hu 
Type of cell line ESC 
Origin Human 
Additional origin info Sex: female 
Cell Source Blastocyst 
Clonality Single cell clone 
Method of reprogramming NA 
Genetic Modification YES 
Type of Modification Insertional mutagenesis, heterozygous 
Associated disease DiGeorge Syndrome 
Gene/locus DGCR8 
Method of modification CRISPR/Cas9 
Name of transgene or 
resistance 




Date archived/stock date 28.05.2020. 
Cell line repository/bank NA 
(continued on next column)  
(continued ) 
Unique stem cell line 
identifier 
HVRDe009-A-1 
Ethical approval HuES9 NIH Approval number: NIHhESC-09-0022 and 
Health Care Research Council, Human Reproduction 
Committee in Hungary (in Hungarian: Egészségügyi 
Tudományos Tanács, Humán Reprodukciós Bizottság 
(ETT HRB) Approval number: 6681/2012-EHR  
Resource utility 
The generated HuES9DGCR8+/− cell line may help the better under-
standing of the molecular mechanisms underlying the complex symp-
toms of the DGS. Furthermore, this in vitro model system can be used for 
examinations of miRNA processing, pharmacological testing and drug 
screening. 
Resource details 
The DG syndrome is the most common micro-deletion syndrome 
associated with a broad range of developmental features affecting the 
cardiovascular, nervous, and immune systems. These abnormalities are 
caused by heterozygous deletions of chromosome 22q11.2 affecting 
about 40–50 protein-coding genes and about 40 non-protein coding 
genes. The exact cellular and biological phenotype of this chromosomal 
disease is difficult to understand due to the complex genetic back-
ground. The primary candidate gene in the deleted region is the DG 
syndrome critical region gene 8 (DGCR8), which is the essential cofactor 
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for Drosha in primary miRNA processing (Tomari and Zamore, 2005). 
We aim to study the effect of DGCR8 on cell differentiation and the 
function of mature cell types, to understand its role in the disease. For 
this purpose, we generated a heterozygous mutant human embryonic 
stem cell line by a CRISPR/Cas9-based knock-out/knock-in method 
(Fig. 1A). Unique sequences in Exon 3, which were applied to knock out 
DGCR8 expression in mouse embryonic stem cells (Yeom et al., 2006.), 
were used to design an appropriate sgRNA for targeting DGCR8 
Fig. 1. Generation and characterization of a DGCR8 mutant human embryonic stem cell line HVRDe009-A-1.  
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(Supplementary file A). The synthesized oligo was cloned into a px330 
vector (Addgene #42230), carrying the Cas9 nuclease, meanwhile, a 
specific, self-cleaving NHEJ donor vector (Tálas et al., 2017) containing 
CAG promoter-driven GFP and Puromycin resistance genes (Kolacsek 
et al., 2011) was constructed to disrupt DGCR8 expression. HuES9 cells 
were electroporated with the 2 plasmids, and after puromycin selection, 
GFP expressing single-cell clones were established and expanded in 
puromycin containing mTeSR medium on Matrigel coated plates. Clones 
were genotyped using the inverse PCR method and one out of 20 single- 
cell clones showed the targeted integration in a heterozygous manner. 
Sanger sequencing of the integrated transgene showed a 16 bp long 
NHEJ repair product upstream of the donor DNA (Fig. 1A and Supple-
mentary file B). To exclude possible off-target insertions, predicted sites 
were sequenced, moreover, one copy of GFP was demonstrated by 
quantitative real-time PCR (Supplementary file G and C) (Kolacsek et al., 
2011) providing uniform GFP expression (Fig. 1F). The cells maintained 
stem cell-like morphology and normal karyotype after transfection, 
antibiotic selection, and single-cell cloning (Fig. 1B and C). The cell line 
was also free of mycoplasma (Supplementary file D). Western blot 
analysis of DGCR8 in the HuES9DGCR8+/− hESCs showed decreased 
DGCR8 expression compared to the wild-type HuES9 cells (Fig. 1D and 
Supplementary file E). HuES9 DGCR8+/− cells constantly expressed plu-
ripotency markers OCT4 and NANOG (Fig. 1G and I left panel). More-
over, flow cytometry analysis showed over 99% expression of SSEA4 
(Fig. 1E). We further investigated the differentiation capacity of the 
HuES9DGCR8+/− cells by in vitro embryoid body (EB) formation. Im-
munostaining and real-time qPCR analysis confirmed continuous 
decline of pluripotency marker NANOG and the trilineage differentia-
tion potential of HuES9DGCR8+/− by the expression of ectoderm (TUJ1, 
PAX6) mesoderm (TBXT, SMA) and endoderm (AFP) markers (Fig. 1H 
and I). Short tandem repeat (STR) analysis confirmed the identity of 
HuES9DGCR8+/− cells (Supplementary file F). Here we describe a single 
cell derived, heterozygous DGCR8 knock-out/ GFP knock-in, human 
embryonic stem cell line (Table 1 and 2). 
1. Materials and methods 
1.1. Cell culturing 
HuES9 and the generated HuES9DGCR8+/− cell lines were maintained 
on Matrigel®-coated plates (Corning) in mTeSR1 (Stem Cell Technolo-
gies) media. HuES9DGCR8+/− culture media was supplemented with 0.8 
µM puromycin (Thermofisher Scientific). Cells were passaged with 
Accutase (Thermofisher Scientific) and were replaced in mTeSR1-Y 
(mTeSR1 supplemented with 10 µM Y27632-2HCl (Selleckchem)). 
1.2. CRISPR/Cas9 genome editing 
The sgRNA for the precise genome editing was designed using the 
Zhang lab’s guide design tool (http://crispr.mit.edu/). The sgRNA oli-
gonucleotides were cloned into pX330-U6-Chimeric_BB-CBh-hSpCas9 
(Addgene #42230) plasmid. The GFP and Puromycin resistance genes 
were cloned into the donor plasmid (Tálas et al., 2017). 4 × 106 HuES9 
cells were electroporated in Amaxa Nucleofector using the Human Stem 
Cell Nucleofector™ Kit (Lonza) with the A-23 program, then plated onto 
Matrigel®-coated plates, in mTeSR1-Y. For cloning, GFP expressing cells 
were plated in Matrigel®-coated 96-well plates, in mTeSR1-Y supple-
mented with 30% MEF-CM (DMEM, supplemented with 15% FBS), 
harvested from mouse embryonic fibroblast (MEF) culture (Thermo-
fisher Scientific). Single-cell clones were expanded and screened by PCR 
and Sanger sequencing for determination of integration site and po-
tential off-target modifications. 
1.3. Western blot 
After briefly sonicated, samples were run on 8% acrylamide gels, 
then electroblotted onto PVDF membranes (BioRad). Membranes were 
blocked by 5% milk/TBS-Tween, and incubated with Anti-DGCR8 
antibody (Table 2) overnight at 4 ◦C. Membranes were then incubated 
with Anti-Rabbit IgG secondary antibody (Table 2) for 60 min at room 
temperature (RT). For signal detection ECL reagent (Thermofisher Sci-
entific) was used, and the membranes were exposed to Agfa films. Anti- 
beta Actin antibody (Table 2) was used to normalize DGCR8 expression. 
DGCR8 protein level in HuES9DGCR8+/− cell line relative to parental cell 
line and normalized to beta-actin endogenous control is indicated. 
1.4. In vitro spontaneous differentiation 
hESC colonies were first dissociated with Collagenase (Thermofisher 
Scientific) and cultured in suspension on low attachment plates in EB 
medium (KO-DMEM supplemented with 20% FBS, 1 mM L-GLU, 1% 
non-essential amino acids, and 0,1 mM ß-mercaptoethanol) (Thermo-
fisher Scientific) for 6 days. Then embryoid bodies (EBs) were trans-
mitted onto 0.1% gelatin (Thermofisher Scientific) coated 24 well tissue 
culture plates or confocal chamber slides (Nalgene) and allowed to 
differentiate for another 12 days in DMEM supplemented with 10% FBS. 
The derivatives of EBs were characterized by immunocytochemical 
staining and by qPCR. 
Table 1 
Characterization and validation.  
Classification Test Result Data 
Morphology Photography normal Fig. 1 panel B 





Fig. 1 panel I 
Fig. 1 panel E 
Genotype Karyotype (G-banding) and 
resolution 
46XX, 
Resolution 450–500 bands per haploid chromosome set 
Fig. 1 panel C 
Identity  DNA Profiling Performed Supplementary file panel F 
STR analysis 17 sites tested, all matching between HuES9wt and 
HuES9DGCR8+/−
Mutation analysis (IF 
APPLICABLE) 
Sanger sequencing Heterozygous mutation, 
off-target validation 
Fig. 1 panel A and Supplementary file 
panel B, G 
Copy number determination One insertion in genome Supplementary file panel C 
Microbiology and virology Mycoplasma Mycoplasma testing /Negative Supplementary file panel D 
Differentiation potential Embryoid body formation Immunocytochemistry: 
AFP, SMA and B-III- 
TUBULIN 
mRNA expression: AFP, BRY and PAX6 
Fig. 1 panels H and I 
Donor screening (OPTIONAL) NA   
Genotype additional info 
(OPTIONAL) 
NA    
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1.5. Immunofluorescent staining and flow cytometry 
Cells were fixed, blocked, and permeabilized as described previously 
(Erdei et al., 2014.). Next, cells were incubated separately with primary 
antibodies (Table 2) for 60 min at RT. Cells were then incubated with 
corresponding secondary antibodies for 60 min at RT. Cell nuclei were 
stained with DAPI. SSEA4 Flow Cytometry analysis was performed as 
described previously (Erdei et al., 2014.). 
1.6. Real-time PCR analysis (RT-PCR) 
Total RNA was isolated using TRIzol Reagent (Thermofisher Scien-
tific). cDNA samples were synthesized from 400 ng of total RNA using 
the Promega Reverse Transcription System. RT-PCR analyses were 
performed using TaqMan® assays (Table 2) and analyzed by the Ste-
pOne™ Real-Time PCR System (Thermofisher Scientific). All quantita-
tive gene expression data were normalized to the expression level of 
RPLP0. 
1.7. Karyotype and STR analysis 
Karyotyping and STR analysis were performed by UD-GenoMed 
Medical Genomic Technologies Ltd. 
1.8. Mycoplasma test 
MycoAlert™ Mycoplasma Detection Kit was used according to the 
manufacturer’s instructions (Lonza). 
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Homolya, András Tálas and Orsolya Kolacsek for advice and technical 
assistance. The HuES9 cell line was kindly provided by Douglas A. 
Melton, Harvard University. The Addgene plasmid pX330-U6- 
Chimeric_BB-CBh-hSpCas9 (#42230) was originally deposited by Feng 
Zhang. 
Funding 
This study was funded by the National Brain Research Program 
(NAP) of Hungary (grant numbers: 2017-1.2.1-NKP-2017-00002 to ÁA 
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Table 2 
Reagents details.  
Antibodies used for immunocytochemistry/flow-cytometry  





Rabbit anti-DGCR8 1:1000 Abcam, Cat# 
ab191875, RRID: n/a 
Loading control 
(WB) 




Mouse anti-Oct3/4 1:50 Santa Cruz 















R and D Systems Cat# 
FAB1435A, RRID: 
AB_494994 























Alexa Fluor 488 
1:250 Thermo Fisher 









Alexa Fluor 488 
1:250 Thermo Fisher 






Anti-Rabbit IgG 1:5000 Thermo Fisher 




Target Forward/Reverse primer (5′-3′) 
Pluripotency 
Marker(qPCR) 












PAX6 Hs00240871_m1 (Thermo Fisher Scientific) 
House-Keeping 
Gene (qPCR) 
RPLP0 Hs99999902_m1 (Thermo Fisher Scientific) 
Genotyping and 
sequencing 
DGCR8 Fwd: AGTTTGGCCCATGGGTAGG/Rev: 
GGAACACCCACTGCTTCTGAC 
Inverse PCR CRISPR- 
targeted 
gDNA 



















#4 ZMAT3-For/  
Table 2 (continued ) 
Primers  
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Appendix A. Supplementary data 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.scr.2020.102134. 
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